Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Breast cancer single-nucleotide polymorphisms: statistical significance and clinical utility.

Offit K.

J Natl Cancer Inst. 2009 Jul 15;101(14):973-5. doi: 10.1093/jnci/djp184. Epub 2009 Jun 30. No abstract available.

PMID:
19567420
2.

Luminal B breast tumors are not HER2 positive.

Bhargava R, Dabbs DJ.

Breast Cancer Res. 2008;10(5):404; author reply 405. doi: 10.1186/bcr2134. Epub 2008 Sep 26. No abstract available.

3.

Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.

Milne RL, Benítez J, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Bremer M, Hillemanns P, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Liu J, Li Y, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G, Beesley J; kConFab Investigators; AOCS Group, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Justenhoven C, Ko YD, Haas S, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Turnbull C, Hines S, Renwick A, Rahman N, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Shen CY, Wang HC, Yu JC, Chen ST, Bermisheva M, Nikolaeva T, Khusnutdinova E, Humphreys MK, Morrison J, Platte R, Easton DF; Breast Cancer Association Consortium.

J Natl Cancer Inst. 2009 Jul 15;101(14):1012-8. doi: 10.1093/jnci/djp167. Epub 2009 Jun 30.

4.

Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer.

Maguire P, Margolin S, Skoglund J, Sun XF, Gustafsson JA, Børresen-Dale AL, Lindblom A.

Breast Cancer Res Treat. 2005 Nov;94(2):145-52.

PMID:
16261413
5.

Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.

Richter-Ehrenstein C, Müller S, Noske A, Schneider A.

Int J Surg Pathol. 2009 Aug;17(4):323-6. doi: 10.1177/1066896908327576. Epub 2008 Nov 24.

PMID:
19029173
6.

[Biological features of breast cancer in patients under 35].

Damenia AO, Turkevich EA, Semiglazov VF, Kochetova IA, Gurbanov SS, Bit-Sava EM, Efimenko AV.

Vopr Onkol. 2007;53(6):674-6. Russian.

PMID:
18416136
7.

[Immunohistochemical markers of hormone sensitivity of breast carcinoma].

Simone G, Paradiso A.

Pathologica. 1992 Nov-Dec;84(1094):11-4. Review. Italian. No abstract available.

PMID:
1300527
8.

Estrogen receptor alpha mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from Japanese women.

Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Haruki N, Kobayashi S, Iwase H.

Breast Cancer. 2003;10(1):70-3.

PMID:
12525766
9.

[Prognostic factors of breast cancer].

Tang P, Wei B, Yang WJ, Liu YS, Bu H.

Zhonghua Bing Li Xue Za Zhi. 2011 Feb;40(2):73-6. Chinese. No abstract available.

PMID:
21426799
10.

DCIS prognostic markers: a few new candidates emerge.

Nelson NJ.

J Natl Cancer Inst. 2010 May 5;102(9):588-90. doi: 10.1093/jnci/djq161. Epub 2010 Apr 28. No abstract available.

PMID:
20427428
11.

[Clinical-biological characteristics of infiltrating ductal carcinomas of the breast with estrogen receptor concentrations >300 fmol/mg protein].

Resino C, Arias JI, Del Río MC, Sánchez Hermosa C, Ruibal A.

Rev Esp Med Nucl. 2001 Oct;20(6):503-5. Spanish. No abstract available.

12.

[Cell receptors and proliferation markers in breast cancer].

Czerwenka KF, Schön HJ, Zeillinger R, Kubista E, Spona J.

Gynakol Rundsch. 1989;29 Suppl 2:400-1. German. No abstract available.

PMID:
2558992
13.

Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.

Shin SJ, Simpson PT, Da Silva L, Jayanthan J, Reid L, Lakhani SR, Rosen PP.

Am J Surg Pathol. 2009 Apr;33(4):496-504. doi: 10.1097/PAS.0b013e31818af361.

PMID:
19047897
14.

Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women.

Zheng W, Wen W, Gao YT, Shyr Y, Zheng Y, Long J, Li G, Li C, Gu K, Cai Q, Shu XO, Lu W.

J Natl Cancer Inst. 2010 Jul 7;102(13):972-81. doi: 10.1093/jnci/djq170. Epub 2010 May 18.

15.

Estrogen receptor immunohistochemistry cutoff value: standardization is needed.

Arslan C, Dizdar O, Altundag K.

Hum Pathol. 2010 Jan;41(1):150; author reply 150-1. doi: 10.1016/j.humpath.2009.08.013. Epub 2009 Sep 16. No abstract available.

PMID:
19762068
16.

A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese.

Elgazzar S, Zembutsu H, Takahashi A, Kubo M, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Katagiri T, Miki Y, Nakamura Y.

J Hum Genet. 2012 Dec;57(12):766-71. doi: 10.1038/jhg.2012.108. Epub 2012 Sep 6.

PMID:
22951594
17.
18.

Genetics and breast cancer risk prediction--are we there yet?

Cook NR, Paynter NP.

J Natl Cancer Inst. 2010 Nov 3;102(21):1605-6. doi: 10.1093/jnci/djq413. Epub 2010 Oct 18. No abstract available.

PMID:
20956781
19.

[Specifics of radiotherapy in hormone-dependent breast cancer].

Khmelevskiĭ EV, Kharchenko VP.

Vopr Onkol. 2003;49(6):711-5. Review. Russian. No abstract available.

PMID:
14976914
20.

Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?

Lovelock PK, Spurdle AB, Mok MT, Farrugia DJ, Lakhani SR, Healey S, Arnold S, Buchanan D; kConFab Investigators, Couch FJ, Henderson BR, Goldgar DE, Tavtigian SV, Chenevix-Trench G, Brown MA.

Breast Cancer Res. 2007;9(6):R82.

Supplemental Content

Support Center